AVEO Pharmaceuticals Inc. (AVEO)

0.61
0.00 0.11
NASDAQ : Health Technology
Prev Close 0.61
Open 0.62
Day Low/High 0.60 / 0.63
52 Wk Low/High 0.56 / 3.59
Volume 2.45M
Avg Volume 3.58M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 82.02M
P/E Ratio N/A
Div & Yield N.A. (N.A)
Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

AVEO Oncology To Present At The Barclays Global Healthcare Conference

AVEO Oncology To Present At The Barclays Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce FDA Advisory Committee To Review Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc.

AVEO Oncology To Present At The 2013 RBC Capital Markets’ Healthcare Conference

AVEO Oncology To Present At The 2013 RBC Capital Markets’ Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

New survival data from the phase III study of Aveo's tivozanib were released Tuesday night.

AVEO And Astellas Report Final Overall Survival Results From TIVO-1

AVEO And Astellas Report Final Overall Survival Results From TIVO-1

AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 ( TIvozanib Versus s Orafenib in 1 st line...

Aveo Pharma Readies Survival Update For Kidney Cancer Drug

Aveo Pharma Readies Survival Update For Kidney Cancer Drug

New survival data on Aveo's tivozanib to be presented at a medical meeting next week.

AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call

AVEO Oncology Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Conference Call

AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013.

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO And Astellas Announce Presentations Of Tivozanib Clinical Data At 2013 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be ...

AVEO Announces Closing Of Public Offering

AVEO Announces Closing Of Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock.

AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Announces Exercise Of Over-Allotment Option For Recent Public Offering

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of...

AVEO Prices Public Offering Of Common Stock

AVEO Prices Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.

AVEO Announces Proposed Public Offering Of Common Stock

AVEO Announces Proposed Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock.

J.P. Morgan Healthcare Confab Live Blog Day Two

J.P. Morgan Healthcare Confab Live Blog Day Two

Live coverage of biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

Shake the Bushes

I'm looking for the hot themes or groups of 2013.

13 Biotech Stock Predictions for 2013

13 Biotech Stock Predictions for 2013

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.

AVEO Oncology To Present At The 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology To Present At The 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31 st Annual J.

Put These Flyers Under Your Tree

These stocks may be speculative, but they sport solid sales-growth estimates -- and insiders are buying.  

AVEO Oncology Appoints Robert Epstein, M.D., M.S. To Its Board Of Directors

AVEO Oncology Appoints Robert Epstein, M.D., M.S. To Its Board Of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein, M.

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

5 Stock Insiders are Gobbling Up

5 Stock Insiders are Gobbling Up

But insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

2013 FDA Drug Approval Decision Calendar

2013 FDA Drug Approval Decision Calendar

A list of stocks with drugs expecting FDA decisions in 2013

Walking Away From the Cliff

Some traders are shutting down for the year rather than trying to game the fiscal cliff.

AVEO And Astellas Announce Initiation Of Patient Enrollment In Phase 2 Trial Of Tivozanib In Combination With Paclitaxel In Patients With Advanced Triple Negative Breast Cancer

AVEO And Astellas Announce Initiation Of Patient Enrollment In Phase 2 Trial Of Tivozanib In Combination With Paclitaxel In Patients With Advanced Triple Negative Breast Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating...

AVEO And Astellas Announce FDA Acceptance Of NDA Filing For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce FDA Acceptance Of NDA Filing For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.

AVEO Oncology To Present At The Deutsche Bank 2012 DbAccess BioFEST Conference

AVEO Oncology To Present At The Deutsche Bank 2012 DbAccess BioFEST Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference on Monday, December 3, 2012 at 4:35 p.

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

AVEO Oncology To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

AVEO Oncology To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:00 p.

TheStreet Quant Rating: D- (Sell)